Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled A Phase ...

Individual brings two decades of industry experience to his new role, and has also previously worked at Refinitiv, Bloomberg ...

Will Douglas has joined IMC Trading as a FX options trader. London-based Douglas brings previous experience in automated ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Quality boots, weather systems, and field accessories were among the highlights of this year's product launches. Here’s what ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Recent data from the New York Federal Reserve Bank and Equifax (NYSE:EFX) highlight a troubling trend in U.S. consumer ...

Reports of inadequate liquidity have been greatly exaggerated, but the high-volatility environment in the first six months of ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...